Literature DB >> 30779029

Flow Cytometry for Non-Hodgkin and Hodgkin Lymphomas.

Emily Glynn1, Lori Soma1, David Wu1, Brent L Wood1, Jonathan R Fromm2.   

Abstract

Multiparametric flow cytometry is a powerful diagnostic tool that permits rapid assessment of cellular antigen expression to quickly provide immunophenotypic information suitable for disease classification. This chapter describes a general approach for the identification of abnormal lymphoid populations by flow cytometry, including B, T, NK, and Hodgkin lymphoma cells suitable for the clinical and research environment. Knowledge of the common patterns of antigen expression of normal lymphoid cells is critical to permit identification of abnormal populations at disease presentation and for minimal residual disease assessment. We highlight an overview of procedures for processing and immunophenotyping non-Hodgkin B- and T-cell lymphomas and also describe our strategy for the sensitive and specific diagnosis of classical Hodgkin lymphoma and nodular lymphocyte predominant Hodgkin lymphoma.

Entities:  

Keywords:  B cells; B-cell lymphoma; Clonality; Flow cytometry; Hodgkin lymphoma; Light-chain restriction; T cells; T-cell lymphoma; T-cell receptor V-beta repertoire analysis

Mesh:

Year:  2019        PMID: 30779029     DOI: 10.1007/978-1-4939-9151-8_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.

Authors:  Jordan Gauthier; Alexandre V Hirayama; Janaki Purushe; Kevin A Hay; James Lymp; Daniel H Li; Cecilia C S Yeung; Alyssa Sheih; Barbara S Pender; Reed M Hawkins; Aesha Vakil; Tinh-Doan Phi; Rachel N Steinmetz; Mazyar Shadman; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2020-05-07       Impact factor: 25.476

2.  Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study.

Authors:  Sebastian Böttcher; Robby Engelmann; Georgiana Grigore; Paula Fernandez; Joana Caetano; Juan Flores-Montero; Vincent H J van der Velden; Michaela Novakova; Jan Philippé; Matthias Ritgen; Leire Burgos; Quentin Lecrevisse; Sandra Lange; Tomas Kalina; Javier Verde Velasco; Rafael Fluxa Rodriguez; Jacques J M van Dongen; Carlos E Pedreira; Alberto Orfao
Journal:  Blood Adv       Date:  2022-02-08

3.  Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.

Authors:  Jordan Gauthier; Evandro D Bezerra; Alexandre V Hirayama; Salvatore Fiorenza; Alyssa Sheih; Cassie K Chou; Erik L Kimble; Barbara S Pender; Reed M Hawkins; Aesha Vakil; Tinh-Doan Phi; Rachel N Steinmetz; Abby W Jamieson; Merav Bar; Ryan D Cassaday; Aude G Chapuis; Andrew J Cowan; Damian J Green; Hans-Peter Kiem; Filippo Milano; Mazyar Shadman; Brian G Till; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2021-01-21       Impact factor: 25.476

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.